{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-23-000058","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.605708+00:00","generated_at":"2026-06-08T05:08:17.896946+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acumen reports Q3 net loss $13M, plans Phase 2 AD trial H1 2024, secures $50M credit facility","bullets":["Phase 2 ALTITUDE-AD trial expected to initiate H1 2024 after positive FDA feedback on study design.","CSF biomarkers p-tau181 (p=0.049) and neurogranin (p=0.037) significantly improved at 60 mg/kg dose in Phase 1.","Credit facility up to $50M from K2 HealthVentures; $30M drawn at closing, matures Nov 2027 or 2028 upon milestones.","Cash and equivalents $282.7M as of Sept 30, 2023; expected to fund operations into H2 2026.","Net loss $13.0M for Q3 2023 vs $10.7M Q3 2022; R&D spend $11.2M vs $8.3M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-23-000058","json":"https://secwatch.observer/filing/0001576885-23-000058.json","markdown":"https://secwatch.observer/filing/0001576885-23-000058.md","text":"https://secwatch.observer/filing/0001576885-23-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000058/0001576885-23-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000058/abos-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:08:17.896946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9b4633c7a80750660ea0af8578f319b9b44fc49","claim":"Acumen Pharmaceuticals, Inc. reported financial results for Q3 2023.","evidence_excerpt":"On November 13, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000058/0001576885-23-000058-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q3 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}